Eligibility
Use the eligibility page when the main question is whether tirzepatide makes clinical sense and what can block a start.
Nao Medical offers provider-guided tirzepatide evaluation for chronic weight management across NYC and Long Island, including candidacy review, insurance and self-pay planning, dose-escalation follow-up, and practical comparison against semaglutide when patients need to decide which GLP-1 path fits better.
Patients searching for tirzepatide or Zepbound-style weight-loss care and trying to understand whether they are a real candidate.
The first visit should clarify candidacy, contraindications, current medications, likely coverage path, and whether tirzepatide still looks like the right fit after review.
Tirzepatide activates both GIP and GLP-1 pathways, while semaglutide targets GLP-1 alone. Head-to-head obesity data and real-world comparisons generally show greater average weight loss with tirzepatide, but semaglutide can still be the better fit when coverage, supply, previous response, side-effect tolerance, or a patient’s broader treatment history points that way.
Good tirzepatide care is not just a prescription. It usually means slow dose escalation, side-effect review, appetite and hydration check-ins, constipation or nausea management, weight and symptom tracking, and clear guidance on when to hold, continue, or escalate the dose.
Use the eligibility page when the main question is whether tirzepatide makes clinical sense and what can block a start.
Use the cost page when the real question is prior authorization, self-pay, pharmacy pricing, or what insurance may actually cover.
Use the monitoring page when patients need clarity on dose escalation, follow-up cadence, and how side effects are managed.
Use the comparison page when the decision is not just whether to start, but which GLP-1 path fits better.
These are the existing Nao Medical weight-loss locations patients can use when they want an in-person path for GLP-1 evaluation, coverage review, and provider follow-up.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods.
View local weight-loss page Get directionsQueens
37-15 23rd Ave, Astoria, NY 11105
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods.
View local weight-loss page Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods.
View local weight-loss page Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A Brooklyn access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods.
View local weight-loss page Get directions
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A Long Island access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities.
View local weight-loss page Get directions
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods.
View local weight-loss page Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods.
View local weight-loss page Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods.
View local weight-loss page Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities.
View local weight-loss page Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods.
View local weight-loss page Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods.
View local weight-loss page Get directionsTirzepatide for weight management is generally reviewed for adults with obesity, or adults with overweight plus a weight-related medical condition, alongside a reduced-calorie diet and increased physical activity. Some adults with obesity and moderate to severe obstructive sleep apnea may also fall within current FDA-approved use. The real decision still depends on medical history, current medications, GI tolerance, thyroid-cancer risk factors, and whether another GLP-1 path already makes more sense.
The main cost question has three separate layers: the visit, the medication, and the follow-up cadence. Insurance may cover the visit while denying the medication, or cover the medication only after prior authorization. Self-pay visits are available when patients want to move forward without waiting on benefit review. Commercial savings programs may help some patients, but those rules change, so the current pharmacy path matters more than a generic online number.
Patients should not use tirzepatide with another tirzepatide-containing product or another GLP-1 agonist. A personal or family history of medullary thyroid carcinoma or MEN2, significant GI motility problems, pancreatitis questions, gallbladder symptoms, and some diabetes-medication combinations all need real review before starting.
The current parent hub remains the broad entry point for medical weight-loss care across NYC and Long Island.
Use the branded Zepbound lane when the patient is searching by brand name and needs direct answers on insurance, self-pay, availability, and Wegovy comparison.
Patients who still need the semaglutide side of the family can move directly into the existing overview page.
Insurance friction is often the practical blocker, so the live coverage guide is still relevant alongside this tirzepatide lane.
Medication choice also depends on refill stability and fulfillment, not just the first prescription.
What patients say about Nao Medical
This gave me the Zepbound and tirzepatide information I was actually looking for instead of a generic weight-loss page.
Helpful that candidacy, cost, monitoring, and comparison were split into separate pages.
The tirzepatide page felt much more practical than the average GLP-1 landing page.
The location links made it easy to turn research into an actual booking step.
This explained the insurance and prior-auth part better than most NYC weight-loss pages.
Helpful that the comparison to semaglutide was built into the same service lane.
Use eligibility for candidacy, cost for coverage and self-pay, monitoring for follow-up expectations, and the comparison page when the real choice is tirzepatide versus semaglutide.
Start with eligibility